Domo signs strategic collaboration agreement with AWS for AI solutions
Investing.com - Roivant Sciences reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Roivant Sciences announced earnings per share of $-0.420 on revenue of $12.53M. Analysts polled by Investing.com EPS of $-0.380 on revenue of $5.7M.
Roivant Sciences 's are down 19.03% and is trading at $5.300 , still down 69.21% from its 52 week high of $16.76 set on Monday, December 20, 2021.
Roivant Sciences shares gained 2.71% to trade at $5.300 in pre-market trade the report.
Roivant Sciences follows other major Healthcare sector earnings this month
Roivant Sciences's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar